Analysts Offer Predictions for Precigen FY2025 Earnings

Precigen, Inc. (NASDAQ:PGEN) – Investment analysts at Cantor Fitzgerald decreased their FY2025 EPS estimates for Precigen in a research note issued to investors on Thursday, May 15th. Cantor Fitzgerald analyst J. Kim now forecasts that the biotechnology company will earn ($0.37) per share for the year, down from their prior estimate of ($0.27). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Precigen’s current full-year earnings is ($0.32) per share.

Separately, HC Wainwright reissued a “buy” rating and issued a $6.00 price target on shares of Precigen in a research report on Thursday, March 20th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $7.00.

Precigen Stock Performance

Shares of PGEN opened at $1.36 on Monday. The company has a 50-day simple moving average of $1.49 and a 200-day simple moving average of $1.31. The firm has a market capitalization of $401.42 million, a P/E ratio of -2.47 and a beta of 1.82. Precigen has a 52 week low of $0.65 and a 52 week high of $2.17.

Precigen (NASDAQ:PGEN) last released its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. Precigen had a negative net margin of 3,521.68% and a negative return on equity of 123.06%. The company had revenue of $1.34 million during the quarter, compared to analysts’ expectations of $0.50 million.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets bought a new position in shares of Precigen during the fourth quarter worth $27,000. Envestnet Asset Management Inc. boosted its position in shares of Precigen by 29.0% during the fourth quarter. Envestnet Asset Management Inc. now owns 26,343 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 5,915 shares in the last quarter. Boothbay Fund Management LLC bought a new position in shares of Precigen during the fourth quarter worth $35,000. Apella Capital LLC bought a new position in shares of Precigen during the first quarter worth $40,000. Finally, RPO LLC bought a new position in shares of Precigen during the fourth quarter worth $47,000. 33.51% of the stock is currently owned by institutional investors.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.